Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer

Lung Cancer

Volumn 44, Issue 3, 2004, Pages 347-353

  Perez, Edith A ^a   Geoffroy, Francois J ^c   Hillman, Shauna ^b   Johnson, Elizabeth A ^a   Farr Jr , Gist H ^d   Tazelarr, Henry D ^b   Hatfield, Alan K ^e   Krook, James E ^f   Maillard, James A ^g   Levitt, Ralph ^h   Marks, Randolph S ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Illinois Oncol Res Assoc CCOP   (United States)

^d Ochsner CCOP   (United States)

^e Carle Cancer Center CCOP   (United States)

^f Duluth CCOP   (United States)

^g MISSOURI VALLEY CANCER CONSORTIUM   (United States)

^h MeritCare Hospital   (United States)

Author keywords

Etoposide; Oral chemotherapy; Paclitaxel; Small cell lung cancer

Indexed keywords

ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; DRUG SYNERGISM; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2342537018     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.12.002     Document Type: Article

References (27)

1. Evans W.K., Shepard F.A., Feld R., Osoba D., Dnag P., Deboer G. VP-16 and cisplatin as first line-therapy for small cell lung cancer. J. Clin. Oncol. 3:1985;1471-1477
2. Johnson D.H. "The guard dies, it does not surrender!" progress in the management of small-cell lung cancer? J. Clin. Oncol. 20(24):2002;4618-4620
3. Chute J.P., Chen T., Feigal E., Simon R., Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J. Clin. Oncol. 17(6):1999;1794
4. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 346:2002;85-91
5. Kelly K. New chemotherapy agents for small cell lung cancer. Chest 2000;117:156-62s.
6. Sandler A. First-line combination chemotherapy for advanced non-small cell lung cancer: the Eastern Cooperative Oncology Group and Southwest Oncology Group experience. Semin. Oncol. 26(5 Suppl. 15):1999;44-51
7. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin. Oncol. 29(3 Suppl. 9):2002;50-54
8. Lilenbaum R.C., Herndon J., List M., Desch C., Watson D., Holland J., et al. Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL) and cost-effectiveness. Proc. ASCO. 21:2002;A2
9. Bengtson E.M., Rigas J.R. A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum. Semin. Oncol. 26(5 Suppl 16):1999;1-6
10. Grant S.C., Gralla R.J., Kris M.G., Orazem J., Kitsis E.A. Single-agent chemotherapy trials in small-cell lung cancer, 1970-90: the case for studies in previously treated patients. J. Clin. Oncol. 10:1992;484
11. Paesmans M., Mascaux C., Berghmans T., Branle F., Lafitte J.J., Lemaitre F., et al. Etoposide (VP16) and cisplatin (CDDP0) merit their key role in chemotherapy (CT) for small cell lung cancer (SCLC): a meta-analysis with a methodology assessment, by the European lung cancer working party (ELCWP). Proc. ASCO. 18:1999;A1830
12. Abratt R.P., Willcox P.A., deGroot M., Goodman H.T., Jansen E.R., Salton D.G. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur. J. Cancer. 27(1):1991;28-30
13. Slevin M.L., Clark P.I., Joel S.P., Malik S., Osborne R.J., Gregory W.M., et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J. Clin. Oncol. 7:1989;1333-1340
14. Clark P.I., Slevin M.L., Joel S.P., Osborne R.J., Talbot D.I., Johnson P.W., et al. A randomized trial of two etoposide schedules in small cell-lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J. Clin. Oncol. 12(7):1994;1427-1435
15. Miller A.A., Herndon J.E. 2nd, Hollis D.R., Elleteron J., Langleben A., Richards F. 2nd, et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the cancer and leukemia group B. J. Clin. Oncol. 13(8):1995;1871-1879
16. Perez E.A., Coe T., Turrell C., Lau D., Campbell D., Gandara D. Phase I study of paclitaxel with oral etoposide in advanced solid tumors. Cancer J. Sci. Am. 2(5):1996;286
17. Bunn P.A. Jr. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin. Oncol. 24(4 Suppl. 12):1997;S12-62-S12-153
18. Hainsworth J.D., Gray J.R., Stroup S.L., Kalman L.A., Patten J.E., Hopkins L.G., et al. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities. J. Clin. Oncol. 15(12):1997;3464-3470
19. Mavroudis J.D., Papadakis E., Veslemes M., Tsiafake X., Stavrakakis J., Kouroussis C., et al. A multicenter randomized trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann. Oncol. 12:2001;463-470
20. Niell H.B., Herndon J.E., Miller A.A., Watson D.M., Sandler A., Kelly K., et al. Randomized phase III intergroup trial (CALGB 9732) of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC). Proc. ASCO. 21:2002;A1169
21. Perez E.A., Buckwalter C.A., Reid J.P. Combinations of paclitaxel and etoposide in the treatment of lung cancer. Semin. Oncol. 23(6 Suppl. 15):1996;21-25
22. Perez E.A., Coe T., Turrell C., Lau D., Campbell D., Gandara D. Phase I study of paclitaxel with oral etoposide in advanced solid tumors. Cancer J. Sci. Am. 2(5):1996;286
23. Duffy D.E., Santner T.J. Confidence intervals for a binomial parameter based on multistaged tests. Biometrics. 43:1978;81-93
24. Kaplan E., Meier P. Nonparametric estimation from incomplete observation. J. Am. Statist. Assoc. 53:1958;456-481
25. Murray N. Small-cell lung cancer at the millennium: radiotherapy innovations improve survival while chemotherapy treatments remain unproven. Clin. Lung Cancer. 1:2000;181-190
26. Lynch J., Herndon J., Lyss A., Mauer A., Watson D., Miller A., et al. Paclitaxel (P) plus topotecan (T) plus GCSF for previously untreated extensive small cell lung cancer (E-SCLC): preliminary analysis of cancer and leukemia group B (CALGB 9430). Proc. ASCO. 19:2000;A1922
27. Johnson E., Lake D., Herndon J.E. 2nd, Box J.W., Lynch T.J., Green M.R. Phase II trial of vinorelbine plus doxorubicin in relapsed small cell lung cancer: CALGB 9332. Am. J. Clin. Oncol. 27(1):2004;19-23